A cancer diagnostics company based in France has leased 9,000 square feet of space in the Virginia Bio+Tech Park and plans to hire 20 people.
HalioDx, which is based in Marseille, France, plans to invest about $1 million in a lab it recently occupied in the biotech park in downtown Richmond, state and local officials announced Wednesday.
The company leased space in the park’s Biotech Eight building on East Jackson Street between 5th and 7th streets. The building had been used as the headquarters of Health Diagnostic Laboratory Inc., a blood testing lab that was once one of the fastest-growing companies in Richmond before it filed for Chapter 11 bankruptcy in June 2015.
HalioDx develops and provides methods for immunological diagnosis of cancers.
With its new lab in Richmond, it plans to expand the availability of its Immunoscore test that enables better management of localized colon cancer.
“Our location in Virginia will allow us to closely interact with all laboratories and hospitals in the region while benefitting from a quite competitive offering from the local authorities, including the Virginia Bio cluster,” HalioDx CEO Stéphane Debono said in a statement.
Economic development representatives in the Richmond area first met with HalioDx officials as part of a French marketing mission in January 2018, according the Greater Richmond Partnership, a regional economic development organization.
HalioDx also considered opening its lab in North Carolina.
“One of the key reasons they chose Richmond is for our talent pipeline and being located near universities producing the talent they need,” said Carrie Roth, president and CEO of the Virginia Bio+Tech Park.